Skip to main content


Figure 1 | Arthritis Research & Therapy

Figure 1

From: Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

Figure 1

Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) at baseline and after 1 and 2 years in a tumor necrosis factor-alpha blocker-naïve cohort of ankylosing spondylitis patients. ns, not significant.

Back to article page